Research Article
Hypomethylation of IL10 and IL13 Promoters in CD4+ T Cells of Patients with Systemic Lupus Erythematosus
Table 1
Patient demographics, medications.
| Patient | Sex/Age | SLEDAI score | Medication |
| 1 | F/35 | 6 | Pred 20 mg/d | 2 | F/33 | 4 | None | 3 | F/22 | 10 | Pred 40 mg/d | 4 | F/27 | 6 | Tria 8 mg/d | 5 | F/29 | 6 | None | 6 | F/26 | 16 | TG 40 mg/d | 7 | F/32 | 12 | Pred 35 mg/d | 8 | F/18 | 8 | None | 9 | F/24 | 4 | Pred 10 mg/d | 10 | F/30 | 11 | Pred 20 mg/d | 11 | F/31 | 16 | Pred 40 mg/d | 12 | F/23 | 6 | Tria 16 mg/d | 13 | F/43 | 10 | Pred 20 mg/d | 14 | F/41 | 14 | Pred 30 mg/d | 15 | F/29 | 10 | Pred 25 mg/d |
|
|
F, female; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; Pred: Prednisone; Tria: Triamcinolone; TG: Tripterygium Glycosides.
|